Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.
2.

Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.

Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ.

Circulation. 2001 Jul 17;104(3):317-24.

3.
4.

Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells.

Itoh Y, Kimoto K, Imaizumi M, Nakatsuka K.

Exp Eye Res. 2007 Mar;84(3):464-72. Epub 2007 Jan 10.

PMID:
17217948
5.

Effect of simvastatin on collagen I deposition in non-infarcted myocardium: role of NF-κB and osteopontin.

Zhang J, Xu Y, Pan L, Chen T, Chen Z, Zhao R.

Can J Physiol Pharmacol. 2010 Nov;88(11):1026-34. doi: 10.1139/y10-075.

PMID:
21076490
6.

[Expression of connective tissue growth factor in cardiomyocyte of young rats with heart failure and benazepril intervention].

Zhang Q, Yi QJ, Qian YR, Li R, Deng B, Wang Q.

Zhonghua Er Ke Za Zhi. 2006 Oct;44(10):733-7. Chinese.

PMID:
17229371
7.

Impact of HMG CoA reductase inhibition on small GTPases in the heart.

Laufs U, Kilter H, Konkol C, Wassmann S, Böhm M, Nickenig G.

Cardiovasc Res. 2002 Mar;53(4):911-20.

PMID:
11922901
8.

Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.

Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, Matsuoka H.

Am J Hypertens. 2008 May;21(5):576-81. doi: 10.1038/ajh.2008.27. Epub 2008 Mar 20.

PMID:
18437150
9.

RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin.

Xu H, Liu P, Liang L, Danesh FR, Yang X, Ye Y, Zhan Z, Yu X, Peng H, Sun L.

Arthritis Rheum. 2006 Nov;54(11):3441-51.

10.

Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway.

Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, Izawa H, Nagata K, Yokota M.

Clin Exp Pharmacol Physiol. 2006 Dec;33(12):1164-71.

PMID:
17184496
11.

Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway.

Al-Rasheed NM, Al-Oteibi MM, Al-Manee RZ, Al-Shareef SA, Al-Rasheed NM, Hasan IH, Mohamad RA, Mahmoud AM.

Drug Des Devel Ther. 2015 Jun 23;9:3217-29. doi: 10.2147/DDDT.S86431. eCollection 2015.

12.

Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice.

Zhang ZZ, Shang QH, Jin HY, Song B, Oudit GY, Lu L, Zhou T, Xu YL, Gao PJ, Zhu DL, Penninger JM, Zhong JC.

J Transl Med. 2013 Sep 25;11:229. doi: 10.1186/1479-5876-11-229.

13.

HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients.

Lin H, Xiao Y, Chen G, Fu D, Ye Y, Liang L, Fan J, Yang X, Sun L, Xu H.

Rheumatol Int. 2011 Nov;31(11):1451-8. doi: 10.1007/s00296-010-1510-6. Epub 2010 May 15.

PMID:
20473500
14.

Statins in heart failure--With preserved and reduced ejection fraction. An update.

Tousoulis D, Oikonomou E, Siasos G, Stefanadis C.

Pharmacol Ther. 2014 Jan;141(1):79-91. doi: 10.1016/j.pharmthera.2013.09.001. Epub 2013 Sep 8. Review.

PMID:
24022031
15.

Inhibitory kappa-B kinase-β inhibition prevents adaptive left ventricular hypertrophy.

Andersen NM, Tang R, Li L, Javan H, Zhang XQ, Selzman CH.

J Surg Res. 2012 Nov;178(1):105-9. doi: 10.1016/j.jss.2012.03.003. Epub 2012 Mar 22.

16.

Thioredoxin 1 is essential for sodium sulfide-mediated cardioprotection in the setting of heart failure.

Nicholson CK, Lambert JP, Molkentin JD, Sadoshima J, Calvert JW.

Arterioscler Thromb Vasc Biol. 2013 Apr;33(4):744-51. doi: 10.1161/ATVBAHA.112.300484. Epub 2013 Jan 24.

17.

Cardiomyocyte-specific expression of CYP2J2 prevents development of cardiac remodelling induced by angiotensin II.

He Z, Zhang X, Chen C, Wen Z, Hoopes SL, Zeldin DC, Wang DW.

Cardiovasc Res. 2015 Mar 1;105(3):304-17. doi: 10.1093/cvr/cvv018. Epub 2015 Jan 24.

18.

Baicalein attenuates angiotensin II-induced cardiac remodeling via inhibition of AKT/mTOR, ERK1/2, NF-κB, and calcineurin signaling pathways in mice.

Wang AW, Song L, Miao J, Wang HX, Tian C, Jiang X, Han QY, Yu L, Liu Y, Du J, Xia YL, Li HH.

Am J Hypertens. 2015 Apr;28(4):518-26. doi: 10.1093/ajh/hpu194. Epub 2014 Oct 31.

PMID:
25362112
19.

Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase.

Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH.

Circulation. 2005 Sep 20;112(12):1763-70. Epub 2005 Sep 12.

20.

Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation.

Indolfi C, Di Lorenzo E, Perrino C, Stingone AM, Curcio A, Torella D, Cittadini A, Cardone L, Coppola C, Cavuto L, Arcucci O, Sacca L, Avvedimento EV, Chiariello M.

Circulation. 2002 Oct 15;106(16):2118-24.

Supplemental Content

Support Center